Visx' Star
This article was originally published in The Gray Sheet
Executive Summary
Ophthalmic laser gains expanded FDA approval for treatment of hyperopic astigmatism using photorefractive keratectomy (PRK). The firm's premarket approval application supplement, covering hyperopia up to 5 D with astigmatism up to 4 D, was recommended for approval by FDA's Ophthalmic Devices Panel in May. The firm received approval in late 1999 for laser-assisted in situ keratomileusis (Lasik) treatment of myopia up to 12 D with or without astigmatism of up to 4 D. Alcon Summit Autonomous' LADARVision gained agency approval Sept. 22 for Lasik treatment of hyperopia up to 6 D, with or without astigmatism up to 6 D, and mixed astigmatism
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.